Edition:
United States

Novo Nordisk A/S (NVO)

NVO on New York Consolidated

49.11USD
20 Sep 2017
Change (% chg)

-- (--)
Prev Close
$49.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,807,272
52-wk High
$49.26
52-wk Low
$30.89

Chart for

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 0.61
Market Cap(Mil.): $95,096.52
Shares Outstanding(Mil.): 1,962.56
Dividend: 0.47
Yield (%): 1.95

Financials

  Industry Sector
P/E (TTM): -- 31.91 16.25
EPS (TTM): -- -- --
ROI: -- 15.14 14.87
ROE: -- 16.37 13.89

BRIEF-Calidus enters joint venture with Novo Resources

* Consideration to Novo is 20 million shares & expenditure commitment of $2 million over 3 years

Sep 19 2017

Novo Nordisk: once-weekly semaglutide reduces glucose, weight more than comparator treatments

COPENHAGEN, Sept 12 Novo Nordisk said at the Annual Meeting of the European Association For The Study Of Diabetes:

Sep 12 2017

Novo Nordisk settles U.S. probe over diabetes drug for $58.7 mln

Sept 5 Novo Nordisk will pay $58.7 million to resolve claims that the drugmaker's sales staff downplayed the importance of a warning about cancer risks on its diabetes medication Victoza's label, the U.S. Justice Department said on Tuesday. (Reporting by Nate Raymond in Boston; Editing by Phil Berlowitz)

Sep 05 2017

BRIEF-Health Canada approves Novo Nordisk's Tresiba, a new basal insulin for type 1 and 2 diabetes

* Health Canada approves Tresiba®, a new basal insulin for type 1 and 2 diabetes

Aug 28 2017

FDA clears Novo Nordisk's diabetes drug to reduce cardiovascular risk

Novo Nordisk said on Friday the U.S. Food and Drug Administration (FDA) approved an expanded use of its diabetes drug to reduce the risk of cardiovascular events such as heart attack and stroke.

Aug 25 2017

UPDATE 2-FDA clears Novo Nordisk's diabetes drug to reduce cardiovascular risk

Aug 25 Novo Nordisk said on Friday the U.S. Food and Drug Administration (FDA) approved an expanded use of its diabetes drug to reduce the risk of cardiovascular events such as heart attack and stroke.

Aug 25 2017

FDA clears Novo Nordisk's diabetes drug to treat heart diseases

Aug 25 Novo Nordisk said on Friday the U.S. Food and Drug Administration (FDA) approved its diabetes drug as a treatment to reduce the risk of three major cardiovascular diseases.

Aug 25 2017

Novo Nordisk's diabetes drug succeeds in key trial (Aug 16)

(This version of the story corrects paragraph 8 to remove reference to absorption of insulin)

Aug 17 2017

CORRECTED-UPDATE 1-Novo Nordisk's diabetes drug succeeds in key trial (Aug 16)

Aug 16 Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.

Aug 17 2017

CORRECTED-Novo Nordisk's diabetes drug succeeds in key trial (Aug 16)

Aug 16 Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.

Aug 17 2017

Competitors

  Price Chg
Sanofi SA (SASY.PA) €83.05 +0.75
Eli Lilly and Co (LLY.N) $82.02 +0.29

Earnings vs. Estimates